亚组分析应考虑血液透析的剂量和频率。

IF 8.5 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Diabetology Pub Date : 2024-11-19 DOI:10.1186/s12933-024-02482-x

Lu Hu, Zhonghua Wang, Xiang He

{"title":"亚组分析应考虑血液透析的剂量和频率。","authors":"Lu Hu, Zhonghua Wang, Xiang He","doi":"10.1186/s12933-024-02482-x","DOIUrl":null,"url":null,"abstract":"The article by Wang et al. titled \"Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis\" demonstrated that new SGLT-2i use in T2DM patients at the onset of dialysis was associated with a reduced long-term risk of all-cause mortality and MACE over a median follow-up duration of 2.0 years. However, the hemodialysis dose and frequency, which are significant confounding factors, were not included in the study's subgroup analysis. We raise concerns about this limitation, which may affect the study's findings.","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"23 1","pages":"416"},"PeriodicalIF":8.5000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575074/pdf/","citationCount":"0","resultStr":"{\"title\":\"Hemodialysis dose and frequency should be considered in subgroup analysis.\",\"authors\":\"Lu Hu, Zhonghua Wang, Xiang He\",\"doi\":\"10.1186/s12933-024-02482-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The article by Wang et al. titled \\\"Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis\\\" demonstrated that new SGLT-2i use in T2DM patients at the onset of dialysis was associated with a reduced long-term risk of all-cause mortality and MACE over a median follow-up duration of 2.0 years. However, the hemodialysis dose and frequency, which are significant confounding factors, were not included in the study's subgroup analysis. We raise concerns about this limitation, which may affect the study's findings.\",\"PeriodicalId\":9374,\"journal\":{\"name\":\"Cardiovascular Diabetology\",\"volume\":\"23 1\",\"pages\":\"416\"},\"PeriodicalIF\":8.5000,\"publicationDate\":\"2024-11-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575074/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Diabetology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12933-024-02482-x\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Diabetology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12933-024-02482-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

Wang等人发表的题为《透析开始时T2DM患者使用SGLT-2抑制剂的死亡率和心血管结局探讨：一项健康全球联合网络分析》的文章表明，透析开始时T2DM患者新使用SGLT-2i与中位随访2.0年期间全因死亡率和MACE的长期风险降低有关。然而，血液透析的剂量和频率是重要的混杂因素，但并未纳入该研究的亚组分析中。我们对这一可能影响研究结果的局限性表示担忧。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Hemodialysis dose and frequency should be considered in subgroup analysis.

The article by Wang et al. titled "Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis" demonstrated that new SGLT-2i use in T2DM patients at the onset of dialysis was associated with a reduced long-term risk of all-cause mortality and MACE over a median follow-up duration of 2.0 years. However, the hemodialysis dose and frequency, which are significant confounding factors, were not included in the study's subgroup analysis. We raise concerns about this limitation, which may affect the study's findings.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cardiovascular Diabetology 医学-内分泌学与代谢

CiteScore

12.30

自引率

15.10%

发文量

240

审稿时长

1 months

期刊介绍： Cardiovascular Diabetology is a journal that welcomes manuscripts exploring various aspects of the relationship between diabetes, cardiovascular health, and the metabolic syndrome. We invite submissions related to clinical studies, genetic investigations, experimental research, pharmacological studies, epidemiological analyses, and molecular biology research in this field.